Abstract:Rev Bras Cineantropom Desempenho Hum 2010, 12(1): [77][78][79][80][81] Resumo -A proteína S100B cerebral tem sido utilizada como um marcador periférico de injúrias do sistema nervoso central (SNC). Entretanto, estudos recentes demonstraram que a S100B também aumenta após o exercício físico, embora o significado desse aumento ainda não esteja bem claro. Apesar de ser liberada, principalmente, por astrócitos, no sistema nervoso central, fontes de produção extracerebral de S100B durante o exercício podem estar im… Show more
“…The increase in blood–brain barrier (BBB) permeability may also explain the rise in S100B during physical activity [ 30 , 51 , 54 ]. Nevertheless, the contribution of S100B from lipolysis and muscular cytolysis seems to be most plausible [ 51 , 55 , 56 ]. Due to the expression of S100B in adipocytes, authors explored the relationship between serum S100B levels and body mass index (BMI) and did not find a significant association [ 57 ].…”
Mild traumatic brain injury (mTBI) accounts for approximately 80% of all TBI cases and is a growing source of morbidity and mortality worldwide. To improve the management of children and adults with mTBI, a series of candidate biomarkers have been investigated in recent years. In this context, the measurement of blood biomarkers in the acute phase after a traumatic event helps reduce unnecessary CT scans and hospitalizations. In athletes, improved management of sports-related concussions is also sought to ensure athletes’ safety. S100B protein has emerged as the most widely studied and used biomarker for clinical decision making in patients with mTBI. In addition to its use as a diagnostic biomarker, S100B plays an active role in the molecular pathogenic processes accompanying acute brain injury. This review describes S100B protein as a diagnostic tool as well as a potential therapeutic target in patients with mTBI.
“…The increase in blood–brain barrier (BBB) permeability may also explain the rise in S100B during physical activity [ 30 , 51 , 54 ]. Nevertheless, the contribution of S100B from lipolysis and muscular cytolysis seems to be most plausible [ 51 , 55 , 56 ]. Due to the expression of S100B in adipocytes, authors explored the relationship between serum S100B levels and body mass index (BMI) and did not find a significant association [ 57 ].…”
Mild traumatic brain injury (mTBI) accounts for approximately 80% of all TBI cases and is a growing source of morbidity and mortality worldwide. To improve the management of children and adults with mTBI, a series of candidate biomarkers have been investigated in recent years. In this context, the measurement of blood biomarkers in the acute phase after a traumatic event helps reduce unnecessary CT scans and hospitalizations. In athletes, improved management of sports-related concussions is also sought to ensure athletes’ safety. S100B protein has emerged as the most widely studied and used biomarker for clinical decision making in patients with mTBI. In addition to its use as a diagnostic biomarker, S100B plays an active role in the molecular pathogenic processes accompanying acute brain injury. This review describes S100B protein as a diagnostic tool as well as a potential therapeutic target in patients with mTBI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.